Magenta Therapeutics, Inc. (MGTA) — Financial statements
Income statement, balance sheet, and cash flow for Magenta Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2↓67.3% | 6 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 146↑75.2% | 83↑50.7% | 55↑17.9% | 47↓7.6% | 51 | |
| General & Administrative Expenses | 34↑37.4% | 25↓3.0% | 26↓7.8% | 28↓0.6% | 28 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 34↑37.4% | 25↓3.0% | 26↓7.8% | 28↓0.6% | 28 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 180↑66.5% | 108↑33.6% | 81↑8.3% | 75↓5.1% | 79 | |
| Total Costs & Expenses | 0.00 | 0.00↓100.0% | 81↑8.3% | 75↓5.1% | 79 | |
| Operating Results | ||||||
| Operating Income | -178↓74.7% | -102↓25.9% | -81↓8.3% | -75↑5.1% | -79 | |
| Depreciation & Amortization | 0.00 | 0.00↓100.0% | 2↓4.7% | 2↑2.1% | 2 | |
| EBITDA | -178↓74.7% | -102↓29.0% | -79↓5.7% | -75↑5.1% | -79 | |
| EBIT | 0.00 | 0.00↑100.0% | -81 | 0.00 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 17 | 0.00↓100.0% | 4↓5.6% | 4 | |
| Interest Income | 16↓7.2% | 17 | 0.00↓100.0% | 4↓5.6% | 4 | |
| Interest Expense | 0.00 | 0.00↑100.0% | -4 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 16↓7.7% | 17↑280.5% | 4↑24.9% | 4↓5.6% | 4 | |
| Income Before Tax | -162↓91.1% | -85↓11.1% | -76↓7.5% | -71↑5.1% | -75 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -4↑20.4% | -6↑2.9% | -6 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.00↑100.0% | -85↓18.0% | -72↓9.9% | -66↑5.2% | -69 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -162↓91.1% | -85↓18.0% | -72↓9.9% | -66↑5.2% | -69 | |
| Bottom-Line Net Income | 0.00↑100.0% | -85↓18.0% | -72↓9.9% | -66↑5.2% | -69 | |
| EPS (Basic) | 0.00↑100.0% | -21.75↑5.6% | -23.05↓1958.0% | -1.12↑21.7% | -1.43 | |
| EPS (Diluted) | 0.00↑100.0% | -21.75↑5.6% | -23.05↓1958.0% | -1.12↑21.7% | -1.43 | |
| Weighted Average Shares | 0.00↓100.0% | 4↑25.0% | 3↓94.7% | 59↑21.3% | 48 | |
| Weighted Average Diluted Shares | 0.00↓100.0% | 4↑25.0% | 3↓94.7% | 59↑21.3% | 48 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.